Document is current
Any future updates will be listed below
-
Authors
Barbieri, Giulia https://orcid.org/0000-0002-3531-0725
Cazzoletti, Lucia https://orcid.org/0000-0002-1429-6282
Melotti, Roberto https://orcid.org/0000-0003-4115-317X
Hantikainen, Essi https://orcid.org/0000-0002-4155-2894
Lundin, Rebecca https://orcid.org/0000-0002-8380-4834
Barin, Laura https://orcid.org/0000-0001-8139-4686
Gögele, Martin https://orcid.org/0000-0003-4785-4348
Riegler, Peter
Ferraro, Pietro Manuel https://orcid.org/0000-0002-1379-022X
Pramstaller, Peter Paul https://orcid.org/0000-0002-9831-8302
Gambaro, Giovanni https://orcid.org/0000-0001-5733-2370
Zanolin, Maria Elisabetta https://orcid.org/0000-0003-3021-2269
Pattaro, Cristian https://orcid.org/0000-0002-4119-0109
- License Information
-
More Information
Article History
Received: 30 May 2024
Accepted: 5 November 2024
First Online: 27 November 2024
Declarations
:
: CP received consultant fees from Quotient Therapeutics. PMF received consultant fees and grants or other support from Allena Pharmaceuticals, Alnylam, Amgen, AstraZeneca, Bayer, Gilead, Novo Nordisk, Otsuka Pharmaceuticals, Rocchetta, Vifor Fresenius, and royalties as an author for UpToDate. All other authors declared no conflict of interest.
: The Ethics Committee of the Healthcare System of the Autonomous Province of Bolzano-South Tyrol approved the CHRIS baseline protocol on 19 April 2011 (21-2011). The study conforms to the Declaration of Helsinki, and with national and institutional legal and ethical requirements.
: The study does not contain any studies with animals performed by any of the authors.
: All participants included in the analysis gave written informed consent.
